ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy
He explains the design of the therapy, and covers the data presented at ASCO. Plus, filing and manufacturing plans, and highlighting this program in other cancers.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.